Updated Data Support Efficacy of Larotrectinib, Entrectinib in NSCLC
Alexander Drilon, MD, discussed updated findings with larotrectinib in <em>NTRK</em> fusion–positive tumors and entrectinib in <em>ROS1</em> fusion–positive NSCLC.<br />
Avapritinib Could Deliver Precision Medicine to Patients With GIST, Says Heinrich
The investigational agent avapritinib demonstrated encouraging response rates in patients with advanced gastrointestinal stromal tumors and PDGFRα D842V-driven GIST, according to findings presented during the 2018 Annual Meeting of the Connective Tissue Oncology Society in Rome, Italy.
Crizotinib Holds Promise for Treating IMFT, Says Schoffski
Patrick Schöffski, MD, MPH, discussed the key findings from the CREATE trial, the next steps for research into inflammatory myofibroblastic tumor, and the regulatory challenges for approval of drugs for rare cancers.
Sangro Highlights Impact of Immunotherapy in HCC
Bruno Sangro, MD, discusses the current landscape for systemic therapies, new directions with immunotherapy, and the need for greater research into combination therapies for HCC.
Expert Stresses Importance of Cultivating Tailored Treatment in HCC
Fabio Piscaglia, MD, discusses the updated 2018 European Association for the Study of the Liver clinical guidelines, which were presented during the 12th International Liver Cancer Association Annual Conference in London, United Kingdom.
2 Commerce Drive Cranbury, NJ 08512